Cargando…

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar

Protease-Activated Receptor-1 (PAR1) is the prototypical member of a family of G protein-coupled receptors that mediate cellular responses to thrombin and related proteases. Thrombin irreversibly activates PAR1 by cleaving the N-terminal exodomain of the receptor, which exposes a tethered peptide li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Cheng, Srinivasan, Yoga, Arlow, Daniel H., Fung, Juan Jose, Palmer, Daniel, Zheng, Yaowu, Green, Hillary F., Pandey, Anjali, Dror, Ron O., Shaw, David E., Weis, William I., Coughlin, Shaun R., Kobilka, Brian K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531875/ https://www.ncbi.nlm.nih.gov/pubmed/23222541 http://dx.doi.org/10.1038/nature11701

Ejemplares similares

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Protease signaling regulates apical cell extrusion, cell contacts, and proliferation in epithelia
por: Schepis, Antonino, et al.
Publicado: (2018)

Crystal structure of the μ-opioid receptor bound to a morphinan antagonist
por: Manglik, Aashish, et al.
Publicado: (2012)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Structure and Dynamics of the M(3) Muscarinic Acetylcholine Receptor
por: Kruse, Andrew C., et al.
Publicado: (2012)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Structure of the human M(2) muscarinic acetylcholine receptor bound to an antagonist
por: Haga, Kazuko, et al.
Publicado: (2012)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Structure of the δ-opioid receptor bound to naltrindole
por: Granier, Sébastien, et al.
Publicado: (2012)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Structure and Function of an Irreversible Agonist-β(2) Adrenoceptor complex
por: Rosenbaum, Daniel M., et al.
Publicado: (2011)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Bound to Lose: Physical Incapacitation Increases the Conceptualized Size of an Antagonist in Men
por: Fessler, Daniel M. T., et al.
Publicado: (2013)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Identifying and quantifying two ligand-binding sites while imaging native human membrane receptors by AFM
por: Pfreundschuh, Moritz, et al.
Publicado: (2015)

Conformational dynamics of androgen receptors bound to agonists and antagonists
por: Gim, Hyo Jin, et al.
Publicado: (2021)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Structure of active β-arrestin1 bound to a G protein-coupled receptor phosphopeptide
por: Shukla, Arun K., et al.
Publicado: (2013)

N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Receptor
por: Zou, Yaozhong, et al.
Publicado: (2012)

Protease-Activated Receptor 1 Mediates Thrombin-Dependent, Cell-Mediated Renal Inflammation in Crescentic Glomerulonephritis
por: Cunningham, Malcolm A., et al.
Publicado: (2000)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode
por: Shiimura, Yuki, et al.
Publicado: (2020)

Neutral protease secretion by human monocytes. Effect of surface-bound immune complexes
Publicado: (1979)

Structural and biochemical analysis of a thermostable membrane-bound stomatin-specific protease
por: Yokoyama, Hideshi, et al.
Publicado: (2013)

Drug Resistance Mutations Alter Dynamics of Inhibitor-Bound HIV-1 Protease
por: Cai, Yufeng, et al.
Publicado: (2014)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_goguq6mbfmql5arms1dad82rq8